ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Imatinib, which functions through inhibiting the activity of BCR-ABL tyrosine kinase, has become the standard treatment for Philadelphia chromosome-positive chronic myeloid leukemia.